NMTC — Neuroone Medical Technologies Share Price
Last trade - 00:00- $6.78m
- $4.74m
- $12.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.8 | ||
| Price to Tang. Book | 1.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -183.44% | ||
| Return on Equity | -119.7% | ||
| Operating Margin | -76.05% | ||
Financial Summary
| Year End 30th Sep | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.24 | 2.12 | 3.45 | 3.45 | 12.1 | 10.22 | 13.33 | 44.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
Directors
- David Rosa PRE (61)
- Mark Christianson CFD (58)
- Steve Mertens CTO (63)
- Jeffrey Mathiesen IND (65)
- Paul Buckman NEC (70)
- Edward Andrle IND (68)
- Christoper Volker CFO (53)
- Emily Johns CAD (35)
- Jason Mills IND (53)
- Last Annual
- September 30th, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 26th, 2017
- Public Since
- November 9th, 2012
- No. of Shareholders
- 111
- No. of Employees
- 18
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 9,105,763
- Address
- 7599 Anagram Dr, EDEN PRAIRIE, 55344-7399
- Web
- https://nmtc1.com
- Phone
- +1 3026587581
- Contact
- Chris Donovan
- Auditors
- BAKER TILLY US LLP
Latest News for NMTC
Upcoming Events for NMTC
Q4 2026 NeuroOne Medical Technologies Corp Earnings Release
Q1 2027 NeuroOne Medical Technologies Corp Earnings Release
Neuroone Medical Technologies Corp Annual Shareholders Meeting
Similar to NMTC
20/20 BIOLABS
NASDAQ Capital Market
Accuray Incorporated
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
AdaptHealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
FAQ
As of Today at 12:17 UTC, shares in Neuroone Medical Technologies are trading at $0.75. This share price information is delayed by 15 minutes.
Shares in Neuroone Medical Technologies last closed at $0.75 and the price had moved by -81.68% over the past 365 days. In terms of relative price strength the Neuroone Medical Technologies share price has underperformed the S&P500 Index by -83.69% over the past year.
The overall consensus recommendation for Neuroone Medical Technologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNeuroone Medical Technologies does not currently pay a dividend.
Neuroone Medical Technologies does not currently pay a dividend.
Neuroone Medical Technologies does not currently pay a dividend.
To buy shares in Neuroone Medical Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.75, shares in Neuroone Medical Technologies had a market capitalisation of $6.78m.
Here are the trading details for Neuroone Medical Technologies:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NMTC
Based on an overall assessment of its quality, value and momentum Neuroone Medical Technologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Neuroone Medical Technologies is $7.27. That is 875.71% above the last closing price of $0.75.
Analysts covering Neuroone Medical Technologies currently have a consensus Earnings Per Share (EPS) forecast of -$0.88 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuroone Medical Technologies. Over the past six months, its share price has underperformed the S&P500 Index by -82.67%.
As of the last closing price of $0.75, shares in Neuroone Medical Technologies were trading -74.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Neuroone Medical Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Neuroone Medical Technologies' management team is headed by:
- David Rosa - PRE
- Mark Christianson - CFD
- Steve Mertens - CTO
- Jeffrey Mathiesen - IND
- Paul Buckman - NEC
- Edward Andrle - IND
- Christoper Volker - CFO
- Emily Johns - CAD
- Jason Mills - IND